Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q3 FY25 Earnings Presentation
30 slides from Dr. Lal Pathlabs's earnings presentation, Jan 30, 2025
Slide 1: Exchange filing cover letter
January 30, 2025 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earnings
Slide 2: Dr. Lal PathLabs Limited Q3 & 9M FY25 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q3 & 9M FY25 Results Presentation January 2025
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentati
Slide 4: Table of Contents
Table of Contents DLPL - At a Glance 4 Q3 FY25 Performance Overview 5 Financials 6 Key Performance Highlights 7 Management Commentary 10 Corporate Overview 11 Shareholding 27 Contact Us 29 DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operat
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 12% 35% 240% 4,857# 280 5,762 3 Year Revenue ROCE Dividend for Pathology & Labs; Geographically Patient Service CAGR Excl. Cash & FY23-24 Radiology tests; spread-out network Centers (PSC’s) Investments Comprehensive Test menu 75+ years of experience in 122 Mn patients
Slide 6: Q3 FY25 Performance Overview
Q3 FY25 Performance Overview Q3 FY25 Q3 FY24 10.7% Rs. 597 crore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 crore PAT Rs. 82 crore 10.3% 20.6 Mn Samples 18.6 Mn 3.8% 6.9 Mn Patients 6.7 Mn SwasthFit +3% 23% Contribution 20% 5 Classification: Restricted
Slide 7: Financials
Financials Particulars (Rs. Cr.) Q3 FY25 Q3 FY24 Gr % YTD Dec’24 YTD Dec’23 Gr % Revenue 597 539 10.7% 1,859 1,681 10.6% Operating Expenditure 443 398 1,332 1,217 EBITDA 154 141 9.6% 527 465 13.3% Margins 25.8% 26.1% 28.3% 27.6% Other Income 25 18 68 51 Depreciation 36 36 106 107 EBIT 144 123 16.8%
Slide 8: Key performance highlights
Key performance highlights • Revenue of Rs. 597 crore in Q3 FY25, a growth of 10.7% Y-o-Y; 9M FY25 revenue of Rs. 1859 crore, an increase of 10.6% Y-o-Y – Volume-led growth achieved through deeper penetration in core markets and calibrated expansion in newer regions of West & South – West region con
Slide 9: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +49 +2,057 +2,372 277 277 280 5,102 5,762 9,247 10,599 10,938 11,619 231 4,731 3,705 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 No. of Patients (Mn) No. of Samples (Mn) +36% +57% 27.3 26.9 27.6 66.0 72.3 78.2
Slide 10: Increasing DLPL reach in Tier 3+
Increasing DLPL reach in Tier 3+ Particulars FY20 FY21 FY22 FY23 FY 24 17% 14% Revenue Tier 3+ 421 544 683 685 789 Tier 3+ 4 Yr. CAGR Total 4 Yr. CAGR Total DLPL Revenue 1330 1,581 2,087 2,017 2227 Contribution from % Revenue from Tier 3+ 32% 34% 33% 34% 35% +3% Tier 3+ Infra Count in Tier 3+* +24 L
Slide 11: Management Commentary
Management Commentary Commenting on the performance, (Hony) Brig. Dr. Commenting on the performance, Dr. Om Manchanda, Commenting on the performance, Mr. Shankha Banerjee, Arvind Lal, Executive Chairman said: Managing Director said: Chief Executive Officer said: “I am pleased that we continue to str
Slide 12: Corporate Overview
WIDENING “0:26 HORIZONS Ox Lat Pathlabs D (3) y SERVING BETTER Corporate Overview
Slide 13: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established Established consumer healthcare brand in diagnostic services brand Pan-India 280 clinical labs (including National Reference Lab at Delhi and Well-positioned integrated Regional Reference labs at Kolkata, Bangalore & Mumbai), 5,762 coverage Patient Service Ce
Slide 14: ABDM - All Milestones achieved, DLPL among early adopters
ABDM - All Milestones acheived, DLPL among early adopters Ayushman Bharat Digital Mission aims to create a National Digital Health Ecosystem to bridge the existing gap amongst different stakeholders of Healthcare ecosystem through digital highways. The mission also enables interoperability and porta
Slide 15: Vision, Mission & Values
Vision, Mission & Values Be the most trusted Customer First healthcare partner, enabling healthier lives VISION Ethics & Integrity To be an undisputed market Quality leader by providing accessible, affordable, timely and quality VALUES healthcare, diagnostics, applying Accountability insights and cu
Slide 16: DLPL Strategy for future growth
DLPL Strategy for future growth Significantly leverage the Enhance high-end test portfolio of strong digital infrastructure super-specialty & bundled test • Deployed AI, data analytics, machine learning • Created specialty verticals like Genevolve to focus on tools to elevate the patient experience
Slide 17: Leveraging digital infrastructure to make life easier for patient
Leveraging digital infrastructure to make life easier for patient New Website Launch Wallet • New age user intuitive website. • Senior Citizen Wallet: Wallet points on every • Responsive , mobile friendly web designs. booking for Senior Citizen Patients. • SEO friendly for improved customer reach •
Slide 18: Summary highlights – Technical Lab Operations
Summary highlights – Technical Lab Operations LACE and the centre Only lab in India to introduce the First lab to introduce the of excellence in Relaunched the Lipid Donor derived cell free DNA ONCOPRO TSO500 Reproductive panels incorporating the (LIQUID BIOPSY) technique for Comprehensive Genomic m
Slide 19: Genevolve: Genetic Testing Division
Genevolve: Genetic Testing Division Onco Genomics Successful completion of 3 years of Launch Wide Test offering with 160+ New Tests Neuro Genomics Wellness Genomics & Pharmacogenomics are upcoming segment Direct reach of 3,000+ Doctors Reproductive Genomics Dedicated Business Development team for Ge
Slide 20: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 97.5% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.3% for Satellite Labs Patent has been granted to Dr. Lal CAP accreditation 2 labs, NABL accreditation 37 PathLabs fo
Slide 21: Quality Control, Laboratory excellence, Capability building
Quality Control Laboratory excellence Capability building Test Recommendation engine NABL 133 implementation D L Shah Gold Award for LPL Project ‘Improving Laboratory Performance by developing an in-house automated process to Risk Based Internal Audits monitor Quality control’ PROJECT NEEV- self lea
Slide 22: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Real time 30 minutes slot visibility & booking D2C- Automated lead management for the patient Digital ID card & ratings of Phlebo Auto Routing engine to dynamically to the patient allocate the booking to nearest available phlebotomist Variable model wh
Slide 23: CSR Projects
CSR Projects LPL Foundation’s flagship program of vocational training focuses on Skilling and Comprehensive School Health Program 1. Skilling: LPL Academy for Laboratory Medicine - Phlebotomist Training 2. Public Health: Comprehensive School Health Program (CSHP) Impact Assessment Metrics (Key findi
Slide 24: Key ESG Initiatives
Key ESG Initiatives Use of Solar Panels Use of Electric E-billing and e- for Power; addition bikes for sample payment receipt to of 50 KW solar collection reduce paper usage plant at NRL Data centre Water saving through virtualization to treatment & reuse of prevent heat and wastewater CO2 emission
Slide 25: Savings of >1.3 million aliquots and >5,210 tons of plastic waste
Savings of >1.3 million aliquots and >5,210 tons of plastic waste in our lab – a strong commitment to sustainability Dr. Lal Pathlabs’ leadership vision focuses on continuous We reduced the need for aliquots by 93% by replacing our previous system configuration1,2 with new, improvement while maintai
Slide 26: Cyber Security Capability
Cyber Security Capability Data Loss • State-of-the-art data loss prevention technology to monitor and prevent the disclosure of information Prevention • Data classification platform for information labeling and handling according to severity of data • Rights management system to enable persistent da
Slide 27: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Shankha Banerjee Executive Chairman Managing Director Whole-time Director Chief Executive Officer Ved Prakash Goel Munender Soperna Jai Prakash Meena Manoj Garg Group Chief Financial Officer & Chief Information
Slide 28: Shareholding as of 31st December, 2024
Shareholding as of 31st December, 2024 27.17% FPI’s & NRI’s 53.91% Promoter and Promoter 8.57% Group Others 10.35% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 27 27 Classification: Restricted
Slide 29: Key Awards & Recognition
Key Awards & Recognition Diagnostic Chain of the Gold Award Year – West Top 100 Global Most Loved QCI – D. L. Shah Quality Business Standard Star SME Best Brands Healthcare GAPIO Excellence in Awarded by the Workplace 2023 Awards - 2022 of the year 2022 2022 Diagnostics Award 2022 prestigious Health
Slide 30: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests